VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Saturday, January 10, 2026

Stock Comparison

Shanxi Xinghuacun Fen Wine Factory Co., Ltd. vs Vertex Pharmaceuticals Incorporated

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Shanxi Xinghuacun Fen Wine Factory Co., Ltd.

600809 · Shanghai Stock Exchange

Market cap (USD)$215.4B
Gross margin (TTM)76.1%
Operating margin (TTM)44.3%
Net margin (TTM)32.7%
SectorConsumer
IndustryBeverages - Wineries & Distilleries
CountryCN
Data as of2025-12-30
Moat score
57/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Shanxi Xinghuacun Fen Wine Factory Co., Ltd.'s moat claims, evidence, and risks.

View 600809 analysis

Vertex Pharmaceuticals Incorporated

VRTX · NASDAQ

Market cap (USD)$119B
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
IndustryBiotechnology
CountryUS
Data as of2026-01-08
Moat score
99/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Vertex Pharmaceuticals Incorporated's moat claims, evidence, and risks.

View VRTX analysis

Comparison highlights

  • Moat score gap: Vertex Pharmaceuticals Incorporated leads (99 / 100 vs 57 / 100 for Shanxi Xinghuacun Fen Wine Factory Co., Ltd.).
  • Segment focus: Shanxi Xinghuacun Fen Wine Factory Co., Ltd. has 2 segments (73.7% in Mid-to-High Priced Liquor (>= RMB130/L)); Vertex Pharmaceuticals Incorporated has 3 segments (99.9% in Cystic Fibrosis CFTR Modulators).
  • Primary market structure: Oligopoly vs Quasi-Monopoly. Pricing power: Strong vs Strong.
  • Moat breadth: Shanxi Xinghuacun Fen Wine Factory Co., Ltd. has 5 moat types across 2 domains; Vertex Pharmaceuticals Incorporated has 7 across 4.

Primary market context

Shanxi Xinghuacun Fen Wine Factory Co., Ltd.

Mid-to-High Priced Liquor (>= RMB130/L)

Market

China premium baijiu (with focus on light-aroma baijiu) and mid-to-high priced spirits

Geography

China

Customer

Consumers and corporate/banquet demand via distributor/retail channels

Role

Brand owner / distiller / wholesaler-distributor orchestrator

Revenue share

73.7%

Vertex Pharmaceuticals Incorporated

Cystic Fibrosis CFTR Modulators

Market

CFTR modulator therapies for cystic fibrosis

Geography

U.S., Europe, Australia, Canada

Customer

Patients (via specialty pharmacies/payers); CF care centers

Role

Drug developer/manufacturer

Revenue share

99.9%

Side-by-side metrics

Shanxi Xinghuacun Fen Wine Factory Co., Ltd.
Vertex Pharmaceuticals Incorporated
Ticker / Exchange
600809 - Shanghai Stock Exchange
VRTX - NASDAQ
Market cap (USD)
$215.4B
$119B
Gross margin (TTM)
76.1%
n/a
Operating margin (TTM)
44.3%
n/a
Net margin (TTM)
32.7%
n/a
Sector
Consumer
Healthcare
Industry
Beverages - Wineries & Distilleries
Biotechnology
HQ country
CN
US
Primary segment
Mid-to-High Priced Liquor (>= RMB130/L)
Cystic Fibrosis CFTR Modulators
Market structure
Oligopoly
Quasi-Monopoly
Market share
n/a
70%-78% (reported)
HHI estimate
n/a
n/a
Pricing power
Strong
Strong
Moat score
57 / 100
99 / 100
Moat domains
Demand, Supply
Legal, Demand, Financial, Supply
Last update
2025-12-30
2026-01-08

Moat coverage

Shared moat types

No overlap yet.

Shanxi Xinghuacun Fen Wine Factory Co., Ltd. strengths

Brand TrustLearning Curve YieldDistribution ControlPreferential Input AccessScale Economies Unit Cost

Vertex Pharmaceuticals Incorporated strengths

IP Choke PointGovernment Contracting RelationshipsSwitching Costs GeneralBenchmark Pricing PowerRegulated Standards PipeService Field NetworkCapacity Moat

Segment mix

Shanxi Xinghuacun Fen Wine Factory Co., Ltd. segments

Full profile >

Mid-to-High Priced Liquor (>= RMB130/L)

Oligopoly

73.7%

Other Liquor (value-tier baijiu and other spirits)

Competitive

25.9%

Vertex Pharmaceuticals Incorporated segments

Full profile >

Cystic Fibrosis CFTR Modulators

Quasi-Monopoly

99.9%

Hemoglobinopathies Gene Therapy (CASGEVY)

Oligopoly

0.1%

Acute Pain (JOURNAVX)

Competitive

n/a

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.